Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
- PMID: 37577239
- PMCID: PMC10412691
- DOI: 10.14218/JCTH.2022.00067S
Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM
Abstract
Drug-induced liver injury (DILI) is a major cause of acute liver injury, liver failure, and liver transplantation worldwide. In recent years, immune checkpoint inhibitors have become widely used. This has led to an increase in DILI, for which pathophysiology and management methods differ significantly from the past. As the number of cases of acute liver injury and liver transplantation due to DILI is expected to increase, information about a DILI is becoming more valuable. DILI is classified into two types according to its etiology: intrinsic DILI, in which the drug or its metabolites cause liver damage that is dose-dependent and predictable; and idiosyncratic DILI, in which liver damage is also dose-independent but unpredictable. In addition, depending on the course of the disease, chronic DILI or drug-induced autoimmune hepatitis may be present. The number of DILI cases caused by antimicrobial agents is decreasing, whereas that caused by drugs for malignant tumors and health foods is increasing. The Roussel Uclaf Causality Assessment Method is widely used to assess causality in DILI. Liver injury is a type of immune-related adverse event. The pattern of hepatic injury in immune-related adverse events is mostly hepatocellular, but mixed type and bile stasis have also been reported. Sclerosing cholangitis caused by immune checkpoint inhibitors has also been reported as a unique type of injury. Treatment mainly comprises withdrawal of immune checkpoint inhibitors and steroid administration; however, mycophenolate mofetil may be considered if the disease is refractory to steroids.
Keywords: Drug-induced liver injury; Immune checkpoint inhibitor; Immune-related adverse events; Updated RUCAM.
© 2023 Authors.
Conflict of interest statement
The authors have no conflict of interests related to this publication.
Figures

Similar articles
-
Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use.Int J Mol Sci. 2023 Jun 29;24(13):10855. doi: 10.3390/ijms241310855. Int J Mol Sci. 2023. PMID: 37446036 Free PMC article. Review.
-
Idiosyncratic Drug-Induced Liver Injury (DILI) and Herb-Induced Liver Injury (HILI): Diagnostic Algorithm Based on the Quantitative Roussel Uclaf Causality Assessment Method (RUCAM).Diagnostics (Basel). 2021 Mar 6;11(3):458. doi: 10.3390/diagnostics11030458. Diagnostics (Basel). 2021. PMID: 33800917 Free PMC article. Review.
-
An Update on Drug-induced Liver Injury.J Clin Exp Hepatol. 2012 Sep;2(3):247-59. doi: 10.1016/j.jceh.2012.05.002. Epub 2012 Sep 21. J Clin Exp Hepatol. 2012. PMID: 25755441 Free PMC article. Review.
-
Molecular Idiosyncratic Toxicology of Drugs in the Human Liver Compared with Animals: Basic Considerations.Int J Mol Sci. 2023 Apr 3;24(7):6663. doi: 10.3390/ijms24076663. Int J Mol Sci. 2023. PMID: 37047633 Free PMC article. Review.
-
Utility of Lymphocyte Transformation Test for Assisting Updated Roussel Uclaf Causality Assessment Method in Drug-Induced Liver Injury: A Case-Control Study.Front Pharmacol. 2022 Mar 10;13:819589. doi: 10.3389/fphar.2022.819589. eCollection 2022. Front Pharmacol. 2022. PMID: 35370653 Free PMC article.
Cited by
-
Hepatotoxicity in Cancer Immunotherapy: Diagnosis, Management, and Future Perspectives.Cancers (Basel). 2024 Dec 29;17(1):76. doi: 10.3390/cancers17010076. Cancers (Basel). 2024. PMID: 39796705 Free PMC article. Review.
-
Copper, Iron, Cadmium, and Arsenic, All Generated in the Universe: Elucidating Their Environmental Impact Risk on Human Health Including Clinical Liver Injury.Int J Mol Sci. 2024 Jun 17;25(12):6662. doi: 10.3390/ijms25126662. Int J Mol Sci. 2024. PMID: 38928368 Free PMC article. Review.
-
Hepatoprotective Effects of Gac (Momordica cochinchinensis) Aril Extract in Acetaminophen-Induced Liver Injury: Modulation of Oxidative Stress, Inflammation, and Glucose Metabolism.J Exp Pharmacol. 2025 Aug 5;17:527-543. doi: 10.2147/JEP.S517411. eCollection 2025. J Exp Pharmacol. 2025. PMID: 40787141 Free PMC article.
-
Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method.Medicines (Basel). 2024 Apr 11;11(4):9. doi: 10.3390/medicines11040009. Medicines (Basel). 2024. PMID: 38667507 Free PMC article. Review.
-
Atorvastatin-Induced Liver Injury With Concurrent Rhabdomyolysis After a Positive Rechallenge.ACG Case Rep J. 2024 Dec 30;12(1):e01570. doi: 10.14309/crj.0000000000001570. eCollection 2025 Jan. ACG Case Rep J. 2024. PMID: 39742213 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous